MetLife Investment Management
OCUL icon

MetLife Investment Management’s Ocular Therapeutix OCUL Stock Holding History

MetLife Investment Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Buy
120,033
+21,270
+22% +$193K 0.01% 1441
2026
Q1 		$837K Sell
98,763
-2,870
-3% -$27.4K ﹤0.01% 1486
2025
Q4 		$1.23M Buy
101,633
+17,567
+21% +$213K 0.01% 1308
2025
Q3 		$983K Hold
84,066
– – ﹤0.01% 1459
2025
Q2 		$780K Sell
84,066
-9,331
-10% -$73K ﹤0.01% 1447
2025
Q1 		$685K Buy
93,397
+663
+0.7% +$5.09K ﹤0.01% 1548
2024
Q4 		$792K Buy
92,734
+2,454
+3% +$23.9K ﹤0.01% 1541
2024
Q3 		$785K Hold
90,280
– – ﹤0.01% 1532
2024
Q2 		$618K Buy
90,280
+30,947
+52% +$191K ﹤0.01% 1607
2024
Q1 		$540K Buy
59,333
+18,685
+46% +$133K ﹤0.01% 1633
2023
Q4 		$181K Hold
40,648
– – ﹤0.01% 2292
2023
Q3 		$128K Hold
40,648
– – ﹤0.01% 2461
2023
Q2 		$210K Hold
40,648
– – ﹤0.01% 2246
2023
Q1 		$214K Buy
40,648
+13,777
+51% +$65.4K ﹤0.01% 2177
2022
Q4 		$75.5K Sell
26,871
-14,011
-34% -$46.4K ﹤0.01% 2687
2022
Q3 		$170K Hold
40,882
– – ﹤0.01% 2407
2022
Q2 		$164K Buy
40,882
+17,968
+78% +$67.9K ﹤0.01% 2444
2022
Q1 		$113K Sell
22,914
-5,491
-19% -$30.4K ﹤0.01% 2600
2021
Q4 		$198K Buy
28,405
+8,223
+41% +$63.9K ﹤0.01% 2059
2021
Q3 		$202K Sell
20,182
-7,957
-28% -$89.4K ﹤0.01% 2097
2021
Q2 		$399K Hold
28,139
– – ﹤0.01% 1707
2021
Q1 		$462K Sell
28,139
-127
-0.4% -$2.45K ﹤0.01% 1570
2020
Q4 		$585K Buy
28,266
+882
+3% +$13.1K 0.01% 1408
2020
Q3 		$208K Buy
27,384
+6,395
+30% +$53.1K ﹤0.01% 1844
2020
Q2 		$175K Hold
20,989
– – ﹤0.01% 1980
2020
Q1 		$104K Buy
+20,989
New +$104K ﹤0.01% 2056
2018
Q3 		– Sell
-17,358
Closed -$117K – 2625
2018
Q2 		$117K Buy
+17,358
New +$119K ﹤0.01% 2151

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MetLife Investment Management's OCUL Position: Q2 2026 in Review

MetLife Investment Management increased its Ocular Therapeutix (OCUL) stake by 22% in Q2 2026, buying an estimated $193K and bringing the position to 120,033 shares worth $1.18M. The position accounts for 0.01% of the portfolio, ranked #1441.

MetLife Investment Management first reported a position in OCUL in Q2 2018 and has held it in 27 quarters since. The position peaked at $1.23M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • MetLife Investment Management held 120,033 shares of Ocular Therapeutix worth $1.18M as of Q2 2026.
  • MetLife Investment Management bought 21,270 Ocular Therapeutix shares in Q2 2026, an estimated $193K.
  • Ocular Therapeutix made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1441 holding.
  • MetLife Investment Management first reported a position in Ocular Therapeutix in Q2 2018 and has held it in 27 quarters since.
  • MetLife Investment Management's Ocular Therapeutix position peaked at $1.23M in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.